Financial Performance - The company's revenue for 2021 was approximately ¥632.95 million, representing a 1.64% increase compared to ¥622.77 million in 2020[16]. - The net profit attributable to shareholders decreased by 28.95% to approximately ¥96.50 million from ¥135.82 million in 2020[16]. - Basic earnings per share dropped by 40.89% to ¥1.20 from ¥2.03 in the previous year[16]. - The total assets at the end of 2021 were approximately ¥1.69 billion, an increase of 3.96% from ¥1.63 billion at the end of 2020[16]. - The net assets attributable to shareholders increased by 1.16% to approximately ¥1.40 billion from ¥1.38 billion in 2020[16]. - The company reported a net profit attributable to shareholders of RMB 96,495,377.13 for the year 2021[158]. - The total distributable profit as of December 31, 2021, was RMB 512,699,980.46 after deducting the previous year's cash dividend distribution[158]. - The company plans to distribute a cash dividend of RMB 5.40 per 10 shares, totaling RMB 43,437,096.72[159]. - The company reported a significant increase in revenue for 2021, reaching approximately 1.5 billion yuan, representing a year-on-year growth of 20%[198]. - The company achieved a net profit of around 300 million yuan in 2021, which is a 15% increase compared to the previous year[149]. Cash Flow and Investments - The net cash flow from operating activities was negative at approximately -¥67.74 million, a decline of 258.24% compared to ¥42.81 million in 2020[16]. - The company reported a significant increase in accounts receivable, which rose to ¥373,660,578.13, accounting for 22.07% of total assets, up from 17.51%[67]. - The company’s investment activities generated a net cash outflow of -¥192,349,728.49, reflecting an 11.65% increase in outflows compared to the previous year[65]. - The company has committed to investment projects, with a total investment amount of 455.83 million CNY planned for the healthcare industry[73]. - The company reported non-operating income of ¥12,246,591.55, primarily from government subsidies, accounting for 12.24% of total profit[66]. Research and Development - The company focuses on R&D in antibiotic, heat-clearing, detoxifying, and gynecological fields, emphasizing innovation and market demand[25]. - Research and development expenses increased by 81.37% to ¥37,015,323.92, primarily due to increased outsourcing of R&D activities[62]. - The company has 87 patents, including 28 invention patents, 24 design patents, and 35 utility model patents, with 5 new invention patents added during the reporting period[44]. - The company is committed to research and development to innovate and launch new products in the pharmaceutical sector[120]. - The company plans to invest 50 million yuan in new product development and technological innovation in 2022[181]. Market Expansion and Sales - The company is actively expanding its market presence, with no new entries or exits from the national medical insurance drug list during the reporting period[40]. - The company plans to optimize market layout and enhance internal management to address challenges in the post-pandemic era[54]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[149]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[120]. - The company plans to enter two new provinces in China, aiming to increase market share by 5% in these regions by the end of 2022[200]. Quality Management and Compliance - The company has implemented a procurement management system to ensure the quality of raw materials, requiring suppliers to meet specific qualifications and undergo quality assessments[32]. - The company has established a quality assurance department responsible for overseeing the entire production process and ensuring compliance with safety and quality standards[33]. - The company emphasizes quality in its procurement process, ensuring that all purchased drugs come from qualified suppliers and adhere to legal standards[36]. - The company has established a comprehensive quality management system to mitigate risks associated with drug quality control, ensuring compliance with safety and efficacy standards[95]. - The company strictly adheres to legal regulations and has established a comprehensive information disclosure system to ensure timely and accurate communication with investors[108]. Governance and Management - The management team has over 20 years of experience in the pharmaceutical industry, ensuring effective execution of the company's strategic goals[43]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[104]. - The company adheres to governance standards, ensuring compliance with laws and regulations, and maintains an independent operational structure from its controlling shareholder[101][103]. - The company has a complete organizational structure and governance system, with no interference from controlling shareholders in its operations[115]. - The company has implemented a performance management system to align employee compensation with company performance[155]. Social Responsibility and Sustainability - The company actively fulfills its social responsibilities and maintains effective communication with stakeholders to promote sustainable development[109]. - The company is committed to sustainable practices, with plans to reduce carbon emissions by 15% over the next three years[149]. - The company has been actively involved in social responsibility initiatives, contributing to public welfare and health improvement, especially during the COVID-19 pandemic[172]. - The company received honors such as "2020 National Pharmaceutical Enterprise Model" and "Lishui City Advanced Collective in Fighting COVID-19" for its efforts in pandemic response[172]. - The company emphasizes compliance with environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[167].

浙江维康药业股份有限公司 2021 年第三季度报告 证券代码：300878 证券简称：维康药业 公告编号：2021-059 浙江维康药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 169,582,040.18 | 2.25% | 501,412,396.64 | 6.14% | | 归属于上市公司股东 | 28,947,158.09 | -7.38% | 92,718,244.39 | 3.83% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 28,399,733.80 | 3.10% | ...

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 331,830,356.46, representing an increase of 8.25% compared to RMB 306,536,483.34 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was RMB 63,771,086.30, up 9.87% from RMB 58,044,715.62 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was RMB 53,767,845.88, an increase of 8.39% compared to RMB 49,605,785.69 in the same period last year[23]. - Basic earnings per share decreased by 17.71% to RMB 0.79 from RMB 0.96 in the same period last year[23]. - The weighted average return on net assets was 4.57%, down 6.01% from 10.58% in the previous year[23]. - The total assets at the end of the reporting period were RMB 1,616,759,929.25, a decrease of 0.74% from RMB 1,628,782,391.06 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were RMB 1,364,586,769.79, down 1.21% from RMB 1,381,254,751.49 at the end of the previous year[23]. Cash Flow and Investment - The net cash flow from operating activities was -RMB 61,793,890.39, a significant decrease of 1,106.97% compared to RMB 6,136,644.18 in the previous year[23]. - The company reported a net cash flow from investment activities of -¥76,646,731.28, which is a 67.89% increase in outflows compared to -¥45,651,919.97 last year, driven by ongoing investments in the health industry park project[60]. - The total amount of funds raised by the company is RMB 72,559.56 million, with RMB 11,326.24 million invested during the reporting period[72]. - The cumulative amount of raised funds invested to date is RMB 53,906.02 million, representing 74.3% of the total raised[72]. - The cash and cash equivalents at the end of the reporting period amount to RMB 1,371,049.26, restricted due to acceptance bill guarantees and electricity deposit guarantees[68]. Research and Development - The company has established multiple research platforms, including provincial high-tech enterprise research centers and post-doctoral workstations, to enhance its core competitiveness in the pharmaceutical sector[43]. - The company is actively involved in new product development, with several products like Bone Spur Capsules and Liver Su Capsules already listed and undergoing regulatory approvals[44]. - Research and development investment rose by 27.93% to ¥9,271,145.23, up from ¥7,246,990.93, reflecting a commitment to innovation[60]. - The company is focusing on research and development in antibiotic, detoxification, and gynecological drug areas, aligning with market demand[43]. Market and Sales Strategy - The company operates a dual sales model, with OTC drugs primarily sold through direct supply and prescription drugs mainly through distribution channels[39]. - The pharmaceutical manufacturing segment generated revenue of ¥244,435,693.30, reflecting a slight increase of 0.06%, while the pharmaceutical commercial segment saw a significant revenue increase of 40.42%, totaling ¥87,394,663.16[40]. - The company plans to launch two new products in Q3 2021, aiming to capture a 5% market share in the new segments[108]. - Future outlook includes an expected revenue growth of 20% for the full year 2021, driven by market expansion and new product launches[109]. Risks and Challenges - The company faces risks including policy risks, drug quality control risks, and management risks due to rapid expansion[4]. - Quality control risks are present due to the complexity of drug production, with measures in place to ensure compliance with safety and efficacy standards[84]. - Management risks are anticipated due to rapid expansion, prompting the company to enhance training and recruitment of management personnel[85]. Corporate Governance and Compliance - The company has committed to protecting the rights of small and medium shareholders and ensuring a fair operating environment for suppliers and customers[97]. - The company emphasizes compliance with labor laws and provides social insurance for employees, including basic medical, unemployment, and pension insurance[99]. - The company actively engages in social responsibility initiatives, including health consultations and charitable donations, especially during the COVID-19 pandemic[100]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[92]. - The company will publicly disclose the reasons for not implementing stabilization measures at the shareholders' meeting and in designated publications[117]. - The company will adhere to the principles of the stabilization plan, ensuring compliance with legal and regulatory requirements[113]. Future Outlook - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 25%[142]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence in the pharmaceutical sector[110]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels by the end of 2021[128].

Financial Performance - The company's revenue for Q1 2021 was ¥132,259,899.28, representing a 7.74% increase compared to ¥122,754,754.51 in the same period last year[7] - Net profit attributable to shareholders was ¥20,272,669.37, up 28.86% from ¥15,732,140.29 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥19,671,120.10, reflecting a 26.09% increase from ¥15,601,124.90 in the previous year[7] - Basic earnings per share decreased by 3.37% to ¥0.2520 from ¥0.2608 year-on-year[7] - Total operating revenue for Q1 2021 was CNY 132,259,899.28, an increase from CNY 122,754,754.51 in the previous period[53] - Net profit for Q1 2021 reached CNY 20,371,610.56, representing a 29.5% increase from CNY 15,732,140.29 in Q1 2020[55] - Operating profit for Q1 2021 was CNY 23,685,671.98, up 24.0% from CNY 19,036,151.28 in the previous year[55] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,004,162.70, a significant decline of 2937.93% compared to -¥1,481,406.73 in the same period last year[7] - Cash flow from operating activities for Q1 2021 was CNY 134,001,330.89, an increase from CNY 119,173,835.10 in the same period last year[62] - The company reported a total cash outflow of 182,501,552.16 CNY from operating activities, which is a 43% increase compared to the previous period[63] - The ending balance of cash and cash equivalents was 484,957,165.65 CNY, down from 593,975,811.41 CNY at the beginning of the period[64] - The company experienced a net decrease in cash and cash equivalents of 109,018,645.76 CNY during the period[64] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,612,680,869.75, a decrease of 0.99% from ¥1,628,782,391.06 at the end of the previous year[7] - Total liabilities decreased to CNY 170,676,977.62 from CNY 207,952,826.21 in the previous period[51] - Current liabilities were CNY 127,641,978.57, down from CNY 177,209,223.49 in the previous period[51] - Total current assets decreased to ¥945.20 million from ¥998.62 million, reflecting a decline of about 5.3%[45] - The total current liabilities increased from CNY 177,209,223.49 to CNY 213,650,314.37, indicating a rise in short-term financial obligations[73] Shareholder Information - The company reported a total of 15,486 common shareholders at the end of the reporting period[11] - The largest shareholder, Liu Zhongliang, holds 60.82% of the shares, totaling 48,921,389 shares[11] - The total equity attributable to shareholders reached CNY 1,456,966,924.27, compared to CNY 1,439,473,664.76 in the previous period[51] Operational Highlights - The company is executing its annual business plan smoothly, with all operations proceeding in an orderly manner[24] - The company faces policy risks due to ongoing national healthcare reforms, which could impact operations if not addressed timely[25] - The company has established a comprehensive quality management system to mitigate risks associated with product quality control[27] - The company is developing generic drug projects and secondary development of key products, which require lower investment and shorter R&D cycles[28] Research and Development - R&D expenses decreased by 30.66% to 4.09 million yuan, attributed to reduced external R&D costs[18] - Research and development expenses for Q1 2021 totaled CNY 4,091,733.61, a decrease of 30.6% from CNY 5,900,941.97 in Q1 2020[55] Investment and Capital Expenditure - The company approved an additional investment of ¥97.21 million in the pharmaceutical health industry park project, increasing the total planned investment to ¥358.62 million[36] - The company has a total of CNY 745,116,281.86 in capital reserves, indicating strong financial backing[71] Risk Management - Management risks are anticipated due to rapid expansion, prompting the company to enhance training for existing management personnel and recruit new staff[29] - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[39] - There were no significant changes in the feasibility of investment projects during the reporting period[36]

Financial Performance - The company's operating revenue for 2020 was ¥622,766,990.78, a decrease of 2.97% compared to ¥641,800,892.91 in 2019[17]. - The net profit attributable to shareholders for 2020 was ¥135,815,760.84, representing an increase of 7.78% from ¥126,012,754.58 in 2019[17]. - The net cash flow from operating activities decreased by 62.03% to ¥42,812,190.40 in 2020, down from ¥112,762,180.44 in 2019[17]. - The total assets at the end of 2020 were ¥1,628,782,391.06, an increase of 85.96% from ¥875,868,201.72 at the end of 2019[17]. - The net assets attributable to shareholders increased by 165.71% to ¥1,381,254,751.49 at the end of 2020, compared to ¥519,843,367.06 at the end of 2019[17]. - The basic earnings per share for 2020 was ¥2.030, a decrease of 2.87% from ¥2.090 in 2019[17]. - The company reported a total of ¥26,442,631.68 in non-recurring gains and losses for 2020, compared to ¥17,027,436.39 in 2019[23]. - The total profit for 2020 was CNY 158,701,874.87, reflecting a year-on-year increase of 7.49%[66]. - The company achieved a net profit of CNY 300 million in 2020, which is an increase of 20% compared to the previous year[161]. Dividend Distribution - The company plans to distribute a cash dividend of 10 RMB per 10 shares to all shareholders, based on a total of 80,439,068 shares[4]. - The cash dividend for 2020 represents 59.23% of the net profit attributable to ordinary shareholders, which was 135,815,760.84 CNY[140]. - The cash dividend for 2020 is the first cash return to shareholders since the company's IPO[140]. - The remaining undistributed profits will be carried forward to the next year, with no stock dividends or capital reserve transfers planned[138]. - The cash dividend distribution plan is subject to approval at the 2020 annual general meeting[138]. Business Overview - The report covers the company's business overview and major financial indicators for the year 2020[12]. - The company’s main business includes the research, production, and sales of modern Chinese and Western medicines, with key products including Yinhuang Dripping Pills and Yimucao Soft Capsules[26]. - The company operates retail pharmacy chains primarily in Lishui and Hangzhou, along with traditional Chinese medicine clinics in both cities[37]. - The company has established multiple research platforms, including provincial-level high-tech enterprise R&D centers and expert workstations, to enhance its core competitiveness in the pharmaceutical field[39]. Market Expansion and Future Outlook - Future outlook remains positive, with a projected revenue growth of 10% for the next fiscal year, driven by market expansion and new product launches[52]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[52]. - Market expansion efforts include targeting tier-2 cities, with plans to open 20 additional stores in these regions[54]. - The company plans to launch three new products in the next quarter, focusing on chronic disease management and preventive care[53]. Research and Development - The company focuses on the R&D of new drugs in areas such as antibiotics, heat-clearing and detoxifying, and gynecology, emphasizing technology development and market demand[39]. - Research and development investment increased by 25%, totaling 100 million RMB, aimed at enhancing product efficacy and safety[53]. - The company plans to enhance its R&D efforts by constructing a new R&D center and upgrading advanced equipment, with a focus on secondary development of existing key products[117]. Risk Management - The company acknowledges potential risks including policy risks, drug quality control risks, and market competition risks, which are detailed in the report[4]. - The report emphasizes the importance of understanding the differences between plans, forecasts, and commitments, urging investors to maintain adequate risk awareness[4]. - The company anticipates management risks associated with rapid expansion, necessitating training and recruitment of management personnel[129]. Compliance and Governance - The company operates under the regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[9]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting manager[3]. - The company has committed to fulfilling all promises made by shareholders and related parties during the reporting period[141]. Share Repurchase and Stock Price Stabilization - The company plans to repurchase shares to stabilize stock prices, ensuring that the repurchase results do not lead to a distribution of equity that does not meet market conditions[146]. - The total amount of funds used for share repurchase will not exceed 50% of the net profit attributable to the parent company for the previous fiscal year[149]. - The company will initiate a board meeting to discuss stock price stabilization plans within three trading days if the stock price conditions are met[147]. Corporate Social Responsibility - The company has made commitments regarding the repayment of social insurance and housing fund contributions for employees, ensuring no financial losses arise from such obligations[181]. - The company is committed to protecting the interests of investors, especially small and medium-sized investors, in case of any legal violations[169].

2020 年第三季度报告 2020 年 10 月 1 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 浙江维康药业股份有限公司 2020 年第三季度报告全文 证券代码：300878 证券简称：维康药业 公告编号：2020-011 浙江维康药业股份有限公司 浙江维康药业股份有限公司 2020 年第三季度报告全文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘忠良、主管会计工作负责人谢立恒及会计机构负责人(会计主 管人员)王静声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江维康药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 1,727,032,588.04 | | 875,868,2 ...